BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

BACKGROUND: The BCR-ABL1 translocation occurs in chronic myeloid leukemia (CML) and in 25% of cases with acute lymphoblastic leukemia (ALL). The advent of tyrosine kinase inhibitors (TKI) has fundamentally changed the treatment of CML. However, TKI are not equally effective for treating ALL. Further...

Descripción completa

Detalles Bibliográficos
Autores principales: Quentmeier, Hilmar, Eberth, Sonja, Romani, Julia, Zaborski, Margarete, Drexler, Hans G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041785/
https://www.ncbi.nlm.nih.gov/pubmed/21299849
http://dx.doi.org/10.1186/1756-8722-4-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041785/
https://www.ncbi.nlm.nih.gov/pubmed/21299849
http://dx.doi.org/10.1186/1756-8722-4-6

Ejemplares similares